Cerebrovascular enigma: Moyamoya disease etiology, identification, and management

Abstract

Moyamoya disease is a sporadic cerebrovascular malady categorized by progressive stenosis of the internal carotid arteries and successive development of friable collateral vessels in the brain. The primary root of Moyamoya disease remains undefined, with a genetic predisposition playing an essential role. Familial cases show autosomal dominant inheritance patterns, Chained to particular genetic mutations. Genetic factors cooperating with environmental factors add to disease development. The moyamoya disease mostly occurs in East Asian countries like Korea and Japan. It has global impact. Its occurrence percentage shows demographic variations, with a greater prevalence among females and diverse age-related occurrence in childhood and adulthood. These patterns show genetic and environmental factors' interconnected linkage. Clinical Manifestations show transient, ischemic strokes, ischemic attacks and intracranial hemorrhages. Clinical signs vary between children and adults, with the later more susceptible to strokes. Cognitive impairment and motor discrepancies also arise due to compromised cerebral perfusion. Diagnosis depends on clinical assessment, neuroimaging, and angiography. Imaging techniques like Magnetic Resonance Imaging (MRI) and Computed Tomography (CT) scans identify cerebral ischemic or hemorrhagic events. Cerebral angiography confirms the diagnosis by revealing a characteristic collateral vessel formation resembling a "puff of smoke." Treatment management includes revascularization procedures, such as direct or indirect bypass surgeries, to improve cerebral blood flow. Medical therapies, including antiplatelet agents, aim to reduce thrombotic risks. Continuing follow-up is crucial to calculate treatment-efficacy and disease progression.

Keywords

• Moyamoya disease
• Etiology
• Epidemiology
• Clinical presentation
• diagnosis
• treatment

References

1. Demartini Z, Teixeira BCA, Koppe GL, Maranha Gatto LA, Roman A, Munhoz RP. Moyamoya disease and syndrome: a review. Radiol Bras [Internet]. 2022 Feb 9 [cited 2023 Jul 31];55(1). Available from: /pmc/articles/PMC8864689/
2. Suzuki J. Moyamoya Disease. 1986 [cited 2023 Aug 17]; Available from: http://link.springer.com/10.1007/978-3-642-95483-2
3. Miao W, Zhao PL, Zhang YS, Liu HY, Chang Y, Ma J, et al. Epidemiological and clinical features of Moyamoya disease in Nanjing, China. Clin Neurol Neurosurg. 2010 Apr 1;112(3):199–203.
4. Kavitha J, Sivakrishnan S. Review on Moyamoya (Puff of Smoke)-A Rarest Disease. Pharmacophore [Internet]. 2020 [cited 2023 Aug 17];11(4):1–4. Available from: http://www.pharmacophorejournal.com
5. Cao L, Dong Y, Sun K, Li D, Wang H, Li H, et al. Experimental Animal Models for Moyamoya Disease: A Species-Oriented Scoping Review. Front Surg. 2022 Jul 1;9:929871.
6. Fox BM, Dorschel KB, Lawton MT, Wanebo JE. Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease. Front Neurol. 2021 Sep 3;12:661578.
7. Ihara M, Yamamoto Y, Hattori Y, Liu W, Kobayashi H, Ishiyama H, et al. Moyamoya disease: diagnosis and interventions. Lancet Neurol [Internet]. 2022 Aug 1 [cited 2023 Aug 17];21(8):747–58. Available from: http://www.thelancet.com/article/S147444222200165X/fulltext
8. Kundishora AJ, Peters ST, Pinard A, Duran D, Panchagnula S, Barak T, et al. DIAPH1 Variants in Non–East Asian Patients With Sporadic Moyamoya Disease. JAMA Neurol [Internet]. 2021 Aug 1 [cited 2023 Aug 17];78(8):993–1003. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/2781029

9. Zanoni P, Steindl K, Sticht H, Oneda B, Joset P, Ivanovski I, et al. The genetic landscape and clinical implication of pediatric Moyamoya angiopathy in an international cohort. Eur J Hum Genet 2023 317 [Internet]. 2023 Apr 4 [cited 2023 Aug 17];31(7):784–92. Available from: https://www.nature.com/articles/s41431-023-01320-0
10. Scott RM, Smith ER. Moyamoya disease and moyamoya syndrome. N Engl J Med. 2009 Mar 19;360(12):1226–37. Kim JS. Moyamoya disease: epidemiology, clinical features, and diagnosis. J Stroke. 2016;18(1):2–11.
11. Mertens R, Graupera M, Gerhardt H, Bersano A, Tournier-Lasserve E, Mensah MA, et al. The Genetic Basis of Moyamoya Disease. Transl Stroke Res 2021 131 [Internet]. 2021 Sep 16 [cited 2023 Aug 17];13(1):25–45. Available from: https://link.springer.com/article/10.1007/s12975-021-00940-2
12. Letchuman V, Ampie L, Mastorakos P, Raper DMS, Kellogg RT, Park MS. Experimental animal models for the study of moyamoya disease. Neurosurg Focus [Internet]. 2021 Sep 1 [cited 2023 Aug 17];51(3):E4. Available from: https://thejns.org/focus/view/journals/neurosurg-focus/51/3/article-pE4.xml
13. Rallo MS, Akel O, Gurram A, Sun H. Experimental animal models for moyamoya disease and treatment: a pathogenesis-oriented scoping review. Neurosurg Focus [Internet]. 2021 Sep 1 [cited 2023 Aug 17];51(3):E5. Available from: https://thejns.org/focus/view/journals/neurosurg-focus/51/3/article-pE5.xml
14. Furtado S V., Basu E, Mehta A, Vala K, Mohan D. Surgical Outcome of Encephaloduroarteriomyosynangiosis for Moyamoya Disease. Neurol India [Internet]. 2021 Sep 1 [cited 2023 Aug 17];69(5):1259. Available from: https://www.neurologyindia.com/article.asp?issn=0028- 3886;year=2021;volume=69;issue=5;spage=1259;epage=1264;aulast=Furtado
15. Gupta A, Tyagi A, Romo M, Amoroso KC, Sonia F. Moyamoya Disease: A Review of Current Literature. 2020;
16. Jeon JP, Hong EP, Ha EJ, Kim BJ, Youn DH, Lee S, et al. Genome-wide association study identifies novel susceptibilities to adult moyamoya disease. J Hum Genet 2023 [Internet]. 2023 Jun 26 [cited 2023 Aug 17];1–8. Available from: https://www.nature.com/articles/s10038-023-01167-9
17. Fang YC, Wei LF, Hu CJ, Tu YK. Pathological Circulating Factors in Moyamoya Disease. Int J Mol Sci 2021, Vol 22, Page 1696 [Internet]. 2021 Feb 8 [cited 2023 Aug 17];22(4):1696. Available from: https://www.mdpi.com/1422-0067/22/4/1696/htm
18. Wang Y, Mambiya M, Li Q, Yang L, Jia H, Han Y, et al. RNF213 p.R4810K Polymorphism and the Risk of Moyamoya Disease, Intracranial Major Artery Stenosis/Occlusion, and Quasi-Moyamoya Disease: A Meta-Analysis. J Stroke Cerebrovasc Dis. 2018 Aug 1;27(8):2259–70.
19. Miyatake S, Miyake N, Touho H, Nishimura-Tadaki A, Kondo Y, Okada I, et al. Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology [Internet]. 2012 Mar 13 [cited 2023 Aug 19];78(11):803–10. Available from: https://n.neurology.org/content/78/11/803
20. Wang Y, Zhang Z, Wei L, Zhang Q, Zou Z, Yang L, et al. Predictive role of heterozygous p.R4810K of RNF213 in the phenotype of Chinese moyamoya disease. Neurology [Internet]. 2020 Feb 18 [cited 2023 Aug 19];94(7):e678–86. Available from: https://n.neurology.org/content/94/7/e678
21. Wetzel-Strong SE, Detter MR, Marchuk DA. The pathobiology of vascular malformations: insights from human and model organism genetics. J Pathol [Internet]. 2017 Jan 1 [cited 2023 Aug 17];241(2):281–93. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/path.4844
22. Hamauchi S, Shichinohe H, Houkin K. Review of past and present research on experimental models of moyamoya disease. Brain Circ [Internet]. 2015 [cited 2023 Aug 17];1(1):88. Available from: https://journals.lww.com/brci/fulltext/2015/01010/review_of_past_and_present_research_on.12.aspx
23. Kathuveetil A, Sylaja PN, Senthilvelan S, Chandrasekharan K, Banerjee M, Jayanand Sudhir B. Vessel Wall Thickening and Enhancement in High-Resolution Intracranial Vessel Wall Imaging: A Predictor of Future Ischemic Events in Moyamoya Disease. Am J Neuroradiol [Internet]. 2020 Jan 1 [cited 2023 Aug 17];41(1):100–5. Available from: https://www.ajnr.org/content/41/1/100
24. Masuda J, Ogata J, Yutani C. Smooth muscle cell proliferation and localization of macrophages and T cells in the occlusive intracranial major arteries in moyamoya disease. Stroke [Internet]. 1993 [cited 2023 Aug 17];24(12):1960–7. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.str.24.12.1960
25. Achrol AS, Guzman R, Lee M, Steinberg KG. Pathophysiology and genetic factors in moyamoya disease. Neurosurg Focus [Internet]. 2009 Apr 1 [cited 2023 Aug 17];26(4):E4. Available from: https://thejns.org/focus/view/journals/neurosurg-focus/26/4/article-pE4.xml
26. Lin R, Xie Z, Zhang J, Xu H, Su H, Tan X, et al. Clinical and Immunopathological Features of Moyamoya Disease. PLoS One [Internet]. 2012 Apr 27 [cited 2023 Aug 17];7(4):e36386. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0036386
27. Suzuki J, Kodama N. Moyamoya disease--a review. Stroke [Internet]. 1983 [cited 2023 Aug 17];14(1):104–9. Available from: https://www.ahajournals.org/doi/abs/10.1161/01.str.14.1.104
28. Smith ER, Scott RM. Moyamoya: Epidemiology, Presentation, and Diagnosis. Neurosurg Clin N Am [Internet]. 2010 Jul 1 [cited 2023 Aug 17];21(3):543–51. Available from: http://www.neurosurgery.theclinics.com/article/S104236801000029X/fulltext
29. Lai PMR, Patel NJ, Frerichs KU, Patel AB, Aziz-Sultan MA, Ogilvy CS, et al. Direct vs Indirect Revascularization in a North American Cohort of Moyamoya Disease. Neurosurgery [Internet]. 2021 Aug 1 [cited 2023 Aug 17];89(2):315–22. Available from: https://journals.lww.com/neurosurgery/fulltext/2021/08000/direct_vs_indirect_revascularization_in_a_north.21.a spx
30. Ghaffari-Rafi A, Ghaffari-Rafi S, Leon-Rojas J. Socioeconomic and demographic disparities of moyamoya disease in the United States. Clin Neurol Neurosurg. 2020 May 1;192:105719.
31. Zhang H, Zheng L, Feng L. Epidemiology, diagnosis and treatment of moyamoya disease (Review). Exp Ther Med [Internet]. 2019 Mar 1 [cited 2023 Aug 19];17(3):1977–84. Available from: http://www.spandidos-publications.com/10.3892/etm.2019.7198/abstract
32. Naqvi S, Yadav G, Jennings M. Citation: Syed Naqvi, Garima Yadav, Marilena Jennings (2021) Moyamoya Disease: The Intersection of Medical Illness and Mental Distress in Children and Adolescents. Intern Jour psych [Internet]. 2021 [cited 2023 Aug 19];6(1):18–21. Available from: www.opastonline.com
33. Lee DJ, Liebeskind DS. Characterization of inpatient moyamoya in the United States: 1988-2004. Front Neurol. 2011 Jul 4;JUL:10234.
34. Nanba R, Kuroda S, Tada M, Ishikawa T, Houkin K, Iwasaki Y. Clinical features of familial moyamoya disease. Child’s Nerv Syst [Internet]. 2006 Mar 30 [cited 2023 Aug 17];22(3):258–62. Available from: https://link.springer.com/article/10.1007/s00381-005-1230-5
35. Wang KC, Phi JH, Lee JY, Kim SK, Cho BK. Indirect revascularization surgery for moyamoya disease in children and its special considerations. Korean J Pediatr [Internet]. 2012 [cited 2023 Aug 17];55(11):408. Available from: /pmc/articles/PMC3510269/
36. Nadarajan V, Perry RJ, Johnson J, Werring DJ. Transient ischaemic attacks: mimics and chameleons. Pract Neurol [Internet]. 2014 Feb 1 [cited 2023 Aug 17];14(1):23–31. Available from: https://pn.bmj.com/content/14/1/23
37. Kim JS. No Title. 2016 [cited 2023 Aug 17];18(1). Available from: /pmc/articles/PMC4747069/ Scott RM. Surgical Treatment of Moyamoya Syndrome in Children. Pediatr Neurosurg [Internet]. 1995 Jan 1 [cited 2023 Aug 17];22(1):39–48. Available from: https://dx.doi.org/10.1159/000121297
38. Yu J, Shi L, Guo Y, Xu B, Xu K. Progress on Complications of Direct Bypass for Moyamoya Disease. Int J Med Sci [Internet]. 2016 Jul 5 [cited 2023 Aug 17];13(8):578. Available from: /pmc/articles/PMC4974906/
39. Lee SU, Oh CW, Kwon OK, Bang JS, Ban SP, Byoun HS, et al. Surgical Treatment of Adult Moyamoya Disease. Curr Treat Options Neurol [Internet]. 2018 Jul 1 [cited 2023 Aug 17];20(7):1–14. Available from: https://link.springer.com/article/10.1007/s11940-018-0511-8
40. Hackenberg A, Battilana B, Hebeisen M, Steinfeld R, Khan N. Preoperative clinical symptomatology and stroke burden in pediatric moyamoya angiopathy: Defining associated risk variables. Eur J Paediatr Neurol. 2021 Nov 1;35:130–6.
41. Yang J, Kim SK, Chu MK, Rho Y Il, Phi JH, Lee SY. Headache in Pediatric Moyamoya Disease after Revascularization Surgery. Cerebrovasc Dis [Internet]. 2023 May 30 [cited 2023 Aug 17];52(3):266–74. Available from: https://dx.doi.org/10.1159/000526551
42. Lucas C, Aly S, Touboul C, Sellami R, Guillaume X, Garcia G.

    Patient-Reported Outcome in Two Chronic Diseases: A Comparison of Quality of Life and Response Profiles in Severe Migraine and Severe Asthma

    . Patient Relat Outcome Meas [Internet]. 2020 Feb [cited 2023 Aug 17];Volume 11:27–37. Available from: https://www.tandfonline.com/action/journalInformation?journalCode=dpro20
43. Kobayashi E, Saeki N, Oishi H, Hirai S, Yamaura A. Long-term natural history of hemorrhagic type moyamoya disease in 42 patients. J Neurosurg [Internet]. 2000 Dec 1 [cited 2023 Aug 17];93(6):976–80. Available from: https://thejns.org/view/journals/j-neurosurg/93/6/article-p976.xml
44. Ishimori ML, Cohen SN, Hallegua DS, Moser FG, Weisman MH. Ischemic Stroke in a Postpartum Patient: Understanding the Epidemiology, Pathogenesis, and Outcome of Moyamoya Disease. Semin Arthritis Rheum. 2006 Feb 1;35(4):250–9.
45. Ibrahim N, Baharudin N, Hashim H, Jaya Raman TK, Mohamed Yassin MS. Recurrent Stroke in a Young Man with Moyamoya Disease on Medical Therapy: A Case Report. J Clin Heal Sci. 2022 Feb 23;7(1):67.
46. Saito K, Sone H. [Effect of smoking on diabetes mellitus and dyslipidemia (effect of smoking on glucose and lipid metabolism)]. Nihon Rinsho [Internet]. 2013 Mar 1 [cited 2023 Jun 3];71(3):443–8. Available from: https://europepmc.org/article/med/23631232
47. Kihara S. [Dyslipidemia]. Nihon Rinsho. 2013;71(2):275–9.
48. Zhang H, Zheng L, Feng L. Epidemiology, diagnosis and treatment of moyamoya disease (Review). Exp Ther Med [Internet]. 2019 Mar 1 [cited 2023 Jul 31];17(3):1977–84. Available from: http://www.spandidos-publications.com/10.3892/etm.2019.7198/abstract
49. Uchino H, Ito M, Fujima N, Kazumata K, Yamazaki K, Nakayama N, et al. A novel application of four-dimensional magnetic resonance angiography using an arterial spin labeling technique for noninvasive diagnosis of Moyamoya disease. Clin Neurol Neurosurg. 2015 Oct 1;137:105–11.
50. Kim JE, Jeon JS. An update on the diagnosis and treatment of adult Moyamoya disease taking into consideration controversial issues. https://doi.org/101179/1743132814Y0000000351 [Internet]. 2014 [cited 2023 Aug 17];36(5):407–16. Available from: https://www.tandfonline.com/doi/abs/10.1179/1743132814Y.0000000351
51. Jung YJ, Ahn JS, Kwon DH, Kwun BD. Ischemic complications occurring in the contralateral hemisphere after surgical treatment of adults with moyamoya disease. J Korean Neurosurg Soc. 2011;50(6):492–6.
52. Okuyama T, Kawabori M, Ito M, Sugiyama T, Kazumata K, Fujimura M. Outcomes of Combined Revascularization Surgery for Moyamoya Disease without Preoperative Cerebral Angiography. World Neurosurg. 2022 Sep 1;165:e446–51.
53. Crofford LJ. Use of NSAIDs in treating patients with arthritis. Arthritis Res Ther [Internet]. 2013 Jul 24 [cited 2023 Aug 16];15(SUPPL 3):1–10. Available from: https://link.springer.com/articles/10.1186/ar4174
54. Fox BM, Dorschel KB, Lawton MT, Wanebo JE. Pathophysiology of Vascular Stenosis and Remodeling in Moyamoya Disease. Front Neurol. 2021 Sep 3;12:661578.
55. Suzuki J, Takaku A. Cerebrovascular Moyamoya Disease: Disease Showing Abnormal Net-Like Vessels in Base of Brain. Arch Neurol [Internet]. 1969 Mar 1 [cited 2023 Aug 19];20(3):288–99. Available from: https://jamanetwork.com/journals/jamaneurology/fullarticle/568758
56. O’Sullivan DJ. Cerebrovascular “Moyamoya” disease. Proc Aust Assoc Neurol [Internet]. 1973 Apr 1 [cited 2023 Aug 19];9:73–9. Available from: https://journals.sagepub.com/doi/10.1177/000331977102200408?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub++0pubmed
57. Guo Q, Pei S, Wang QN, Li J, Han C, Liu S, et al. Risk Factors for Preoperative Cerebral Infarction in Infants with Moyamoya Disease. Transl Stroke Res [Internet]. 2023 Jun 14 [cited 2023 Aug 17];1–10. Available from: https://link.springer.com/article/10.1007/s12975-023-01167-z
58. Kuroda S, Fujimura M, Takahashi J, Kataoka H, Ogasawara K, Iwama T, et al. Diagnostic Criteria for Moyamoya Disease - 2021 Revised Version. Neurol Med Chir (Tokyo). 2022 Jul 15;62(7):307–12.
59. Akiyama Y, Mikami T, Mikuni N. Deep Learning-Based Approach for the Diagnosis of Moyamoya Disease. J Stroke Cerebrovasc Dis. 2020 Dec 1;29(12):105322.
60. Houkin K, Nakayama N, Kuroda S, Nonaka T, Shonai T, Yoshimoto T. Novel Magnetic Resonance Angiography Stage Grading for Moyamoya Disease. Cerebrovasc Dis [Internet]. 2005 Oct 1 [cited 2023 Aug 19];20(5):347–54. Available from: https://dx.doi.org/10.1159/000087935
61. KIKUCHI T, TAKAGI Y, NAKAGAWARA J, UENO T, UBUKATA S, HOUKIN K, et al. Neuronal Loss in the Bilateral Medial Frontal Lobe Revealed by 123I-iomazenil Single-photon Emission Computed Tomography in Patients with Moyamoya Disease: The First Report from Cognitive Dysfunction Survey of Japanese Patients with Moyamoya Disease (COSMO-Japan Study). Neurol Med Chir (Tokyo). 2023 Aug 15;2023–0041.
62. Ogasawara K, Takahashi T, Igarashi S, Yabuki M, Omori D, Akamatsu Y, et al. Effect of the addition of 123I-iomazenil single-photon emission computed tomography to brain perfusion single-photon emission computed tomography on the detection accuracy of misery perfusion in adult patients with ischemic moyamoya disease. Ann Nucl Med [Internet]. 2023 May 1 [cited 2023 Aug 17];37(5):280–8. Available from: https://link.springer.com/article/10.1007/s12149-023-01825-0
63. Fan AP, Guo J, Khalighi MM, Gulaka PK, Shen B, Park JH, et al. Long-Delay Arterial Spin Labeling Provides More Accurate Cerebral Blood Flow Measurements in Moyamoya Patients. Stroke [Internet]. 2017 Sep 1 [cited 2023 Aug 17];48(9):2441–9. Available from: https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.117.017773
64. Zhao MY, Fan AP, Chen DYT, Ishii Y, Khalighi MM, Moseley M, et al. Using arterial spin labeling to measure cerebrovascular reactivity in Moyamoya disease: Insights from simultaneous PET/MRI. https://doi.org/101177/0271678X221083471 [Internet]. 2022 Mar 2 [cited 2023 Aug 17];42(8):1493–506. Available from: https://journals.sagepub.com/doi/abs/10.1177/0271678X221083471
65. Hertza J, Loughan A, Perna R, Davis AS, Segraves K, Tiberi NL. Moyamoya Disease: A Review of the Literature. http://dx.doi.org/101080/090842822012721147 [Internet]. 2013 Jan 1 [cited 2023 Aug 17];21(1):21–7. Available from: https://www.tandfonline.com/doi/abs/10.1080/09084282.2012.721147
66. Indorewalla KK, McArdle M, Tomlinson E, Piryatinsky I. Neuropsychological profile associated with Moyamoya disease: A case report. NeuroRehabilitation. 2020 Jan 1;46(4):603–11.
67. Fujimura M, Tominaga T. Diagnosis of Moyamoya Disease: International Standard and Regional Differences. Neurol Med Chir (Tokyo). 2015 Feb 20;55(3):189–93.
68. Parray T, Martin TW, Siddiqui S. Moyamoya disease: A review of the disease and anesthetic management. J Neurosurg Anesthesiol [Internet]. 2011 Apr [cited 2023 Aug 17];23(2):100–9. Available from: https://journals.lww.com/jnsa/fulltext/2011/04000/moyamoya_disease__a_review_of_the_disease_and.3.aspx
69. Seo WK, Kim JY, Choi EH, Kim YS, Chung JW, Saver JL, et al. Association of antiplatelet therapy, including cilostazol, with improved survival in patients with moyamoya disease in a nationwide study. J Am Heart Assoc [Internet]. 2021 Mar 2 [cited 2023 Aug 17];10(5):1–21. Available from: https://www.ahajournals.org/doi/abs/10.1161/JAHA.120.017701
70. Scott RM, Smith ER. Moyamoya Disease and Moyamoya Syndrome. https://doi.org/101056/NEJMra0804622 [Internet]. 2009 Mar 19 [cited 2023 Aug 17];360(12):1226–37. Available from: https://www.nejm.org/doi/full/10.1056/nejmra0804622
71. Mayeku J, Lopez-Gonzalez MA. Current Surgical Options for Moyamoya Disease. 2020; Deng X, Ge P, Wang S, Zhang D, Zhang Y, Wang R, et al. Treatment of moyamoya disease. Clin Neurosurg [Internet]. 2018 [cited 2023 Aug 17];65:62–5. Available from: https://journals.lww.com/neurosurgery/fulltext/2018/09001/treatment_of_moyamoya_disease.17.aspx
72. Griessenauer CJ, Lebensburger JD, Chua MH, Fisher WS, Hilliard L, Bemrich-Stolz CJ, et al. Encephaloduroarteriosynangiosis and encephalomyoarteriosynangiosis for treatment of moyamoya syndrome in pediatric patients with sickle cell disease. J Neurosurg Pediatr [Internet]. 2015 Jul 1 [cited 2023 Aug 17];16(1):64–73. Available from: https://thejns.org/pediatrics/view/journals/j-neurosurg-pediatr/16/1/article-p64.xml
73. Kim SK, Wang KC, Kim IO, Dong SL, Cho BK. Combined encephaloduroarteriosynangiosis and bifrontal encephalogaleo(periosteal)synangiosis in pediatric moyamoya disease. Neurosurgery [Internet]. 2008 Jun [cited 2023 Aug 17];62(6 SUPPL.). Available from: https://journals.lww.com/neurosurgery/fulltext/2008/06001/combined_encephaloduroarteriosynangiosis_and.52.aspx
74. Gao G, Hao F, Wang Q-N, Wang X-P, Liu S, Wang M, et al. Surgical outcomes following encephaloduroarteriosynangiosis in moyamoya disease associated with hyperhomocysteinemia. Brain Behav [Internet]. 2023 Jun 29 [cited 2023 Aug 17];e3093. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/brb3.3093
75. Fiaschi P, Scala M, Piatelli G, Tortora D, Secci F, Cama A, et al. Limits and pitfalls of indirect revascularization in moyamoya disease and syndrome. Neurosurg Rev [Internet]. 2021 Aug 1 [cited 2023 Aug 17];44(4):1877–87. Available from: https://link.springer.com/article/10.1007/s10143-020-01393-1
76. Shimizu T, Aihara M, Yamaguchi R, Sato K, Aishima K, Yoshimoto Y. Large Craniotomy Increases the Risk of Minor Perioperative Complications in Revascularization Surgery for Moyamoya Disease. World Neurosurg. 2020 Sep 1;141:e498–507.
77. Wang KC, Yang LY, Lee JE, Wu V, Chen TF, Hsieh ST, et al. Combination of indirect revascularization and endothelial progenitor cell transplantation improved cerebral perfusion and ameliorated tauopathy in a rat model of bilateral ICA ligation. Stem Cell Res Ther [Internet]. 2022 Dec 1 [cited 2023 Aug 18];13(1):1–14. Available from: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-03196-1
78. Adelson PD, Scott RM. Pial Synangiosis for Moyamoya Syndrome in Children. Pediatr Neurosurg [Internet]. 1995 Jan 1 [cited 2023 Aug 18];23(1):26–33. Available from: https://dx.doi.org/10.1159/000120932
79. Riordan CP, Storey A, Cote DJ, Smith ER, Michael Scott R. Results of more than 20 years of follow-up in pediatric patients with moyamoya disease undergoing pial synangiosis. J Neurosurg Pediatr [Internet]. 2019 Mar 1 [cited 2023 Aug 18];23(5):586–92. Available from: https://thejns.org/pediatrics/view/journals/j-neurosurg-pediatr/23/5/article-p586.xml
80. Montaser A, Driscoll J, Smith H, Karsten MB, Day E, Mounlavongsy T, et al. Long-term clinical and radiographic outcomes after pial pericranial dural revascularization: a hybrid surgical technique for treatment of anterior cerebral territory ischemia in pediatric moyamoya disease. J Neurosurg Pediatr [Internet]. 2021 Jul 2 [cited 2023 Aug 18];28(3):351–9. Available from: https://thejns.org/pediatrics/view/journals/j-neurosurg-pediatr/28/3/article-p351.xml.